Hacettepe University Institute of Oncology, Department of Medical Oncology, Sıhhiye, 06100 Ankara, Turkey.
Cancer Treat Rev. 2011 Apr;37(2):127-32. doi: 10.1016/j.ctrv.2010.07.003. Epub 2010 Aug 11.
Constituting about 1-2% of all tumors of the pancreas, pancreatic neuroendocrine tumors (PNETs) are a subgroup of gastroenetropancreatic neuroendocrine tumors (GEP-NETs) with distinct tumor genetics, biology, and clinicopathological features. Surgical resection is amenable only in a minority of the cases so systemic therapies are considered in most of them. The goals of medical treatment are to control the associated symptoms and signs of the specific tumors and to shrink the tumor mass. Somatostatin analogues can, not only decrease the secretion of peptides and inhibit their functions but also stop tumor growth. Other medical options for limiting tumor growth include interferon, systemic chemotherapy, and targeted therapies including, angiogenesis inhibitors, epidermal growth factor inhibitors, and mTOR inhibitors. Newer agents are tested and the treatment options expected to increase in the near future. Meanwhile optimal use of the available therapeutic strategies is critical.
胰腺神经内分泌肿瘤（pancreatic neuroendocrine tumors，PNETs）约占胰腺所有肿瘤的 1-2%，是胃胰神经内分泌肿瘤（gastroenetropancreatic neuroendocrine tumors，GEP-NETs）的一个亚组，具有独特的肿瘤遗传学、生物学和临床病理特征。只有少数情况下可以进行手术切除，因此大多数情况下都需要采用系统治疗。医学治疗的目的是控制特定肿瘤的相关症状和体征，并缩小肿瘤体积。生长抑素类似物不仅可以减少肽的分泌并抑制其功能，还可以阻止肿瘤生长。其他限制肿瘤生长的医学选择包括干扰素、全身化疗以及靶向治疗，包括血管生成抑制剂、表皮生长因子抑制剂和 mTOR 抑制剂。新的药物正在被测试，预计在不久的将来治疗选择将会增加。与此同时，最佳利用现有的治疗策略至关重要。
